ANIP logo

ANI PHARMACEUTICALS INC

ANIPNASDAQ
πŸ† #1997 by market capEarnings Feb 26US Equity
$68.55β–Ό $0.58 (βˆ’0.84%)
Market closed Β· at close
πŸ””
Track ANIP
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.8%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$1.56B
Small Cap
πŸ“ˆRevenue Growth (YoY)
43.8%
High Growth
πŸ“ŠGross Margin
67.8%
High
πŸ’΅FCF Margin
17.0%
Healthy
βš–οΈP/S Ratio
1.5x
Cheap
Otter Score
76
Strong
No chart data available for ANIP.

Trading Snapshot

Day Range
$68.49 – $70.22
52-Week Range
$67.14 – $87.76
Volume (shares)
227,263
Avg Volume (shares)
β€”
Shares Outstanding
22.7M
Next Earnings
2027-02-26

Fundamentals Snapshot

Annual Revenue
$883M
Last Q Revenue
$291M
P/E Ratio
13.2
P/S Ratio
1.5x
EPS (TTM)
$5.51
Dividend Yield
0.00%
Dilution (1yr)
+9.2%
ANIP logo

ANI PHARMACEUTICALS INC

ANIP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$883Mβ–² +43.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
51.0%β–Ό βˆ’13.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$81Mβ–² +13809.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$151Mβ–² +220.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
21.2Mβ–² +9.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$40Mβ–² +$440M YoY
StockOtter Β· stockotter.space

About ANI PHARMACEUTICALS INC

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWireΒ·3d ago

ANI Pharmaceuticals to Present at Upcoming December Investor Conference

PRINCETON, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Compa

Zacks Investment ResearchΒ·5d ago

Here's Why ANI Pharmaceuticals (ANIP) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Defense WorldΒ·5d ago

ANI Pharmaceuticals, Inc. $ANIP Stock Acquired by Aberdeen Group plc

Aberdeen Group plc boosted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) by 23.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The in

Seeking AlphaΒ·15d ago

ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript

ANI Pharmaceuticals, Inc. ( ANIP ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Irina Rivkind Koffler - Vice President of Investor Relations Nikhil Lalwani - President, CEO & Director Mary Pao

MarketBeatΒ·17d ago

ANI Pharmaceuticals Q3 Earnings Call Highlights

ANI Pharmaceuticals NASDAQ: ANIP reported 28% revenue growth for the third quarter of 2026 and announced an offer to acquire Egetis Therapeutics for $560 million in equity value, while lowering its full-year sales outloo

Zacks Investment ResearchΒ·17d ago

ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago a